Home ›
Marginal Zone Lymphoma Lymphoma Trials ›
NCT06134284
Clinical Study of OR for Second-line Treatment of Refractory MZL
The goal of this clinical trial is to test the overall response rate of Orelabrutinib combined with rituximab (OR regimen) for second-line treatment of relapsed/refractory marginal zone lymphoma.
Trial Details
NCT ID NCT06134284
Phase PHASE4
Sponsor Lixia Sheng
Status RECRUITING
Cancer Type Marginal Zone Lymphoma Lymphoma
Interventions Orelabrutinib combined with rituximab
Locations (sample) Hangzhou, Zhejiang, China|30.29365,120.16142 Ningbo, Zhejiang, China|29.87819,121.54945 Ningbo, Zhejiang, China|29.87819,121.54945
Key Eligibility Criteria
Age: 18 years, 80, Sex gender no limitied; histological confirmation of MZL, For splenic marginal zone lymphoma (SMZL) where histological specimens of the spleen were not available, Requirem… at least one two-dimensional measurable lymph node lesion (CT scan or MR / display maximum diameter\> 1.5cm), Or at least one two-dimensional measu… the investigator required systemic treatment for marginal zone lymphoma;
For full eligibility, visit ClinicalTrials.gov .